熱門資訊> 正文
新阿姆斯特丹制药公司宣布其降低胆固醇药物的积极数据
2024-07-29 22:24
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) said that it achieved main goal in its late-stage trial to evaluate obicetrapib in adult patients with heterozygous familial hypercholesterolemia, however falling short of mean reduction in comparison to the mid-stage trial.
- The trial achieved an LS mean reduction of 36.3% compared to placebo at day 84, which was sustained at day 365 with an LS mean LDL-C reduction of 41.5%.
- Obicetrapib lowered median LDL cholesterol by 51% in a phase 2 trial.
- In the trial, obicetrapib was observed to be well-tolerated, with safety results comparable to placebo and no increase in blood pressure.
- The treatment discontinuation rate for the obicetrapib arm was 7.6% versus 14.4% for placebo.
- Source: Press Release
More on NewAmsterdam Pharma
- NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period
- Biggest stock movers today: Crypto stocks, PBI, PHG, and more
- Seeking Alpha’s Quant Rating on NewAmsterdam Pharma
- Historical earnings data for NewAmsterdam Pharma
- Financial information for NewAmsterdam Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
